Sarepta shares plunge 30% as future of its gene therapy appears at risk
1. Sarepta's shares dropped over 30% due to Elevidys treatment concerns. 2. FDA may request a halt on Elevidys shipments amid safety investigations. 3. Two patient deaths linked to Elevidys are under FDA investigation. 4. A third death is reported with a separate experimental gene therapy. 5. Sarepta did not comment on the FDA's investigation status.